| abstract |
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ n n n n n n n n n n wherein n R 1 and R 2 are independently selected from the group consisting of H, CF 3 , halo, C 1-3 alkyl and C 1-3 -alkoxy; n R 3 and R 4 are independently selected from the group consisting of H, CF 3 , halo, CH 3 and OCH 3 ; n R 5 is selected from the group consisting of H, CF 3 , halo, OH, CH 2 OH, C 1-4 alkyl, CH 2 -cyclopropyl and C 1-4 alkoxy, wherein C 1-4 alkyl and C 1-4 alkoxy, may be optionally substituted with one or two OH substituents; n R 6 is selected from the group consisting of C 3-5 alkyl and —CH 2 —C 3-4 cycloalkyl; n R 7 is selected from the group consisting of n n n n n n n n n n n n R 8 is selected from the group consisting of C 1-3 alkyl, C 1-3 alkoxy, CH 2 CN, CH 2 OH, OH, CN and halo; n R 9 is the group —(CHR 10 ) s —(X) t —(CHR 10 ) u —R 11 ; n each R 10 is independently selected from the group consisting of H, OH or CH 2 OH; n R 11 is an isoxazole, —C(O)OH, or a 5- or 6-membered heteroaryl group, wherein the isoxazole or the 5- or 6-membered heteroaryl group may be optionally substituted with one or two halo, NH 2 or CH 3 substituents; n X is CH 2 , NH, O; n r is 0, 1 or 2; n s is 0, 1 or 2; n t is 0 or 1;\ n u is 0, 1 or 2; n with the proviso that no more than two R 10 groups represent OH or CH 2 OH. |